| Private Placement / Financing Transactions
Ablative Solutions: The company raised $76.9 million of Series 2 venture funding from undisclosed investors on November 26, 2025. The company is a developer of catheter-based neurolytic delivery systems designed for therapeutic intervention in hypertension.
Quarry Thera: The company raised $32 million of Series A venture funding from Eli Lilly, Yosemite and Canaan Partners on November 24, 2025. F-Prime Capital also participated in the round. The company is a developer of proximity-driven therapeutics designed to overcome limitations in conventional drug modalities.
Dayra Therapeutics: The company raised $20 million of venture funding from Versant Ventures on November 24, 2025. The company is a developer of oral macrocyclic peptide therapeutics for treating serious diseases with improved bioavailability and target selectivity.
Luminate Medical: The company raised $17.5 million of Series A venture funding in a deal led by 8VC, Atlantic Bridge Capital and ARTIS Ventures on November 24, 2025, putting the company’s pre-money valuation at $19.5 million. SciFounders, Faber Ventures, Metaplanet Holdings, Calm Ventures, Finn Murphy, Steve Pacelli and Lachy Groom also participated in the round. The company is a developer of medical devices for improving cancer treatment delivery and patient outcomes.
MindImmune: The company raised $16.3 million of Series A venture funding from Pfizer Ventures and other undisclosed investors on November 24, 2025, putting the company’s pre-money valuation at $27.15 million. The company is a developer of antibody-based therapeutics targeting central nervous system diseases including neurodegenerative disorders.
Neela Therapeutics: The company raised $12 million of venture funding in the form of convertible debt from Biogen on November 24, 2025. The company is a developer of gene therapies for treating rare pediatric neurogenetic diseases and central nervous system disorders.
BTB Therapeutics: The company raised $6.7 million of venture funding from undisclosed investors on November 30, 2025. The company is a developer of small-molecule RNA splicing modulators for non-opioid pain management and cancer immunotherapy applications.
Sunflower: The company raised $6 million of venture funding in a deal led by Flybridge on November 28, 2025, putting the company’s pre-money valuation at $54 million. Y Combinator, Gaingels and other undisclosed investors also participated in the round. The company is a developer of digital addiction recovery platforms providing behavioral therapy and support for substance use disorders.
Huxley Medical: The company raised $5.9 million of venture funding from undisclosed investors on November 26, 2025. The company is a developer of flexible telehealth platforms providing continuity of care across multiple healthcare settings and locations.
Morphle: The company raised $5 million of Series A venture funding led by Inflexor on November 25, 2025. The company is a developer of an online pathology scanner designed to facilitate pathologists in collaborating with other doctors in real time.
Aurora Cold Plasma Sterilisation: The company raised EUR 3.8 million of venture funding through a combination of debt and equity from Normandie Participations, GO Capital and European Innovation Council on November 27, 2025. The company is a developer of room-temperature plasma sterilization systems for processing heat-sensitive and complex medical devices.
NanoMosaic: The company raised $4 million of venture funding from undisclosed investors on November 24, 2025. The company is a developer of a nanoneedle proteomic beta system designed to assist in proteomics.
BC3 Technologies: The company raised $3.6 million of Series A funding from undisclosed investors on November 26, 2025, putting the company’s pre-money valuation at $36.8 million. The company is a developer of chitosan-based aerosolized hemostatic products for rapid hemorrhage control in emergency and surgical settings.
Axo Longevity: The company raised an undisclosed amount of venture funding from 51Ventures on November 25, 2025. The company is a provider of clinical laboratory testing services designed for the diagnosis and monitoring of autoimmune, hematologic, metabolic, and cardiovascular conditions.
MiCare Path: The company raised Series C and D venture funding on November 25, 2025. The company is a developer of virtual care navigation platforms for coordinating patient care pathways.
|
